http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2392001-C2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10efc646a4dd605c2f09c493718f5b81 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-54 |
filingDate | 2008-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2010-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a108f43da8403c90b1749253155feaa1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7374f09daa3e016bd53ddd10daa5198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4f88e1b2c752b88ffe1243da5ef5e73 |
publicationDate | 2010-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2392001-C2 |
titleOfInvention | Icteric form of hepatitis a in childen with food allergy treatment method |
abstract | FIELD: medicine. n SUBSTANCE: invention belongs to medicine, notably to hepatology, and relates to viral hepatitis A treatment in children with food allergy in acute phase of disease. On admission to hospital patient receives usual complex therapy of hepatitis, complemented with antihistaminic drugs - suprastin or tavegil, and enzymatic drugs - pancreatin or mesym - forte. Suprastin or tavegil is administered ј - 1 tablet after meal two times a day during 7-10 days. Pancreatin or mezym-forte is administered Ѕ-1 tablet 3 times a day during 14-18 days. n EFFECT: method fastens children recovery and reduces frequency of disease residual effects. n 1 ex, 6 tbl, 4 dwg |
priorityDate | 2008-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.